Alternative Health Blog

In a randomized, placebo-controlled study involving 36 patients with non-ischemic chronic heart failure (LVEF<35%, NYHA class >2), supplementation with omega-3 fatty acids (1 g/d or 4 g/d) for a period of 12 weeks was found to be associated with significant reductions in monocyte-platelet aggregates in a dose-dependent manner. Omega-3 fatty acids in a dose of 4 g/d decreased P-selectin and was found to exhibit modest anti-inflammatory effects, reducing interleukin-6 and a trend-wise reduction of hsTNF-alpha. The authors state, "In patients with severe non-ischaemic CHF, treatment with n3-PUFA leads to a dose-dependent decrease of platelet activation and TF. Higher dosage exhibits also anti-inflammatory effects."